FDA Approvals & Biotech Updates: Denali, Sarepta, Corcept & Allogene
The biotech landscape saw a pair of approvals from the Food and Drug Administration this week, offering potential latest options for patients with ovarian cancer and a rare genetic disorder. Denali Therapeutics’ Hunter syndrome drug and Corcept Therapeutics’ treatment for platinum-resistant ovarian cancer both received the green light, as reported in the latest Readout Newsletter from STAT News.
Lifyorli: A New Approach to Ovarian Cancer
Corcept’s Lifyorli (relacorilant) is a first-in-class selective glucocorticoid receptor antagonist, approved for adults battling epithelial ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based chemotherapy. This approval comes nearly four months ahead of schedule, a welcome development for patients with limited treatment options. The drug works by blocking the glucocorticoid receptor, a protein that can contribute to cancer progression in some cases. Pharmaphorum reports that Corcept’s stock surged following the announcement, reflecting investor confidence in the drug’s potential.
Ovarian cancer is often diagnosed at a late stage, making treatment challenging. Platinum-based chemotherapy is a standard first-line treatment, but many patients eventually develop resistance. Lifyorli offers a new avenue for these patients, targeting a different mechanism than traditional chemotherapy. However, it’s important to note that this is not a cure, and further research will be needed to determine the long-term benefits and potential side effects of the drug.
Avlayah: Hope for Hunter Syndrome Patients
Denali Therapeutics’ Avlayah (tividenofusp alfa) received accelerated approval for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. This rare genetic disorder is caused by a deficiency in an enzyme needed to break down certain complex sugars, leading to a buildup of these sugars in the body’s cells. This buildup can cause a range of symptoms, including skeletal abnormalities, cognitive impairment, and organ damage. BioWorld details that the approval came ahead of the previously scheduled PDUFA date of April 5th.
Avlayah is designed to deliver a functional version of the missing enzyme directly to cells, potentially alleviating the symptoms of Hunter syndrome. The accelerated approval pathway allows for earlier access to promising treatments for serious conditions, but it also requires Denali to conduct further studies to confirm the drug’s clinical benefit. Hunter syndrome primarily affects males, and the severity of the condition can vary widely. The approval of Avlayah represents a significant step forward for patients and families affected by this debilitating disease.
Understanding Accelerated Approval
The FDA’s accelerated approval pathway is intended to speed up the availability of drugs that treat serious conditions and fill unmet medical needs. It’s based on a surrogate endpoint – a marker that is reasonably likely to predict clinical benefit. In the case of Avlayah, the surrogate endpoint was likely related to enzyme activity or biomarker levels. However, accelerated approval requires the drug manufacturer to conduct post-market studies to confirm the clinical benefit. If these studies do not demonstrate a meaningful improvement in patient outcomes, the FDA can withdraw the approval.
Sarepta’s RNA Therapies and the Road Ahead
The Readout Newsletter also mentioned Sarepta Therapeutics, which posted early data on new RNA therapies. While the data was described as limited, it prompted investors to reconsider their position after a challenging year for the company. RNA therapies represent a promising new approach to treating genetic diseases, by correcting or compensating for faulty genes. However, these therapies are often complex to develop and manufacture, and their long-term effects are still being studied.
Allogene’s CAR-T Progress
The newsletter also highlighted the anticipated readout from Allogene, a company developing off-the-shelf CAR-T cell therapy. CAR-T therapy involves modifying a patient’s own immune cells to recognize and attack cancer cells. Traditional CAR-T therapy is personalized, meaning that each patient’s cells must be collected, modified, and infused back into the patient. Allogene is working on an “off-the-shelf” version of CAR-T therapy, using cells from healthy donors, which could make the treatment more accessible and affordable. The upcoming study readout is considered a pivotal moment for the company, as it will provide crucial data on the safety and efficacy of its approach.
The FDA approvals of Lifyorli and Avlayah, coupled with the progress at Sarepta and Allogene, underscore the dynamic nature of the biotech industry. These developments offer hope for patients with serious and often rare diseases, but also highlight the challenges and uncertainties inherent in drug development.
What comes next: The coming months will be critical for Denali and Corcept as they continue to gather data on Avlayah and Lifyorli, respectively. The results of these post-market studies will determine the long-term viability of these treatments and their impact on patient care. Similarly, the readout from Allogene’s CAR-T study will be closely watched by the biotech community, as it could pave the way for a new generation of cancer therapies.